1 – 5 of 5
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer : The Primary Results of the PRONOUNCE Randomized Trial
(
- Contribution to journal › Article
- 2015
-
Mark
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
(
- Contribution to journal › Article
- 2013
-
Mark
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Novel and potent small-molecule urotensin II receptor agonists
(
- Contribution to journal › Article